



FOUNDATION FUNDING OPPORTUNITIES: MAY 7, 2021

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

**Have you updated your MGH Researcher profile?
Go to <https://researchers.mgh.harvard.edu/> today!**

1. Surgical Investigator Program, AATS Graham Foundation/American Association for Thoracic Surgery (AATS)

The Surgical Investigator Program supports clinical and translational research by young cardiothoracic surgeons, including topics related to quality and outcomes research, and studies of new and innovative therapies, procedures, and technologies in cardiothoracic surgery. While this program is designed to support early-career development, in 2021, the AstraZeneca sponsored Surgical Investigator award has been specifically designated for mid-career clinical scientists.

AstraZeneca Surgical Investigator Award

Awards to support research proposals focused on the treatment of lung cancer, either in terms of basic science advances, surgical outcomes or the development of quality initiatives. Proposals could be focused on topics such as the following:

- Patient reported outcomes after surgery, specifically as they relate to disease free survival or recurrence.
- Pre- and post-operative molecular testing.
- Optimization of staging and or definition of surgical quality metrics.
- Prognostic biomarkers in patients with surgically resected lung cancer.



Do you want to learn more about identifying external funding opportunities? Please [click here](#) to request a research consultation with **Amy Robb** or see ECOR's website for information on the [Pivot database](#).

Eligibility requirements (partial list):

- Completed his/her formal training in cardiothoracic surgery and be certified or in the process of obtaining certification by the appropriate Thoracic Surgery Board in the United States, Canada or international equivalent;
- Eligibility is for surgical investigators 8-12 years out from their cardiothoracic surgery training, however, candidates who exceed this range are still able to apply;
- Must have evidence of previous independent peer-reviewed grant support in the area of application (preferred but not limited to: Federal NIH R-grant, DOD or VA Merit).

Citizenship: Unspecified

Award Amount: \$100,000-\$200,000 paid over 1-2 years

Indirect Costs: 10%

Application Deadline: July 1, 2021

Website:

https://www.aats.org/aatsimis/AATSWeb/Foundation/Programs/Programs/Surgical_Investigator/Surgical_Investigator_Program.aspx

2. AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship, American Association for Cancer Research (AACR) **NEW!**

The AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship is a joint effort to support and encourage innovative research projects with direct applicability and relevance to ILC and to help establish a successful career path in the field. Research projects may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to invasive lobular carcinoma (ILC).

This fellowship provides a grant to support the salary and benefits of postdoctoral or clinical research fellows working on mentored ILC research projects. A portion of these funds may be designated for non-personnel expenses such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses.

Eligibility requirements (partial list):

- Within five years since degree/residency
- Work under the auspices of a mentor
- Lobular Breast Cancer focus
- Applicants must be AACR members in good standing by the application deadline.

Citizenship: Unrestricted

Award Amount: \$120,000 paid over 2 years

Indirect Costs: None

LOI Deadline: July 6, 2021

(Invited) Application Deadline: September 23, 2021

Website: <https://www.aacr.org/grants/aacr-lobular-breast-cancer-alliance-invasive-lobular-carcinoma-research-fellowship/>

3. AHA Postdoctoral Fellowship, American Heart Association (AHA)

To enhance the training of postdoctoral applicants who are not yet independent. The applicant must be embedded in an appropriate investigative group with the mentorship, support, and relevant scientific guidance of a research mentor. Recognizing the unique challenges that clinicians, in particular, experience in balancing research and clinical activity, this award mechanism aims to be as flexible as possible to enable applicants to develop academic careers in research alongside fulfilling clinical service commitments.

Science Focus:

The AHA funds basic, clinical, behavioral, translational and population research, bioengineering/biotechnology and public health problems broadly related to fulfilling our mission to be a relentless force for a world of longer, healthier lives.

Disciplines:

AHA awards are open to the array of academic and health professionals. This includes but is not limited to all academic disciplines (biology, chemistry, mathematics, technology, physics, etc.) and all health-related professions (physicians, nurses, nurse practitioners, pharmacists, dentists, physical and occupational therapists, statisticians, nutritionists, etc.). Clinical, translational, population, and basic scientists are encouraged to apply.

Eligibility requirements (partial list):

- At the time of award activation, the applicant may have no more than five years of research training or experience since obtaining a post-baccalaureate doctoral-level degree (excluding clinical training).
- AHA believes diversity and inclusion is an essential component to driving its mission and strongly encourages applications by women, underrepresented racial and ethnic groups in the sciences, military veterans, people with disabilities, members of the LGBTQ community, and those who have experienced varied and non-traditional career trajectories.

Citizenship: Unrestricted

Award Amount: 1-2 year grant matches the NIH sliding scale for postdoctoral fellows at the time the AHA publishes its RFA.

Indirect Costs: None

Application Deadline: September 15, 2021

Website: <https://professional.heart.org/en/research-programs/application-information/postdoctoral-fellowship>

4. Fellowships, Biogen

Biogen considers requests to support Clinical Fellowship Programs in Alzheimer's Disease, Multiple Sclerosis and Neuromuscular Disease (SMA and ALS).

We look for programs that:

- Focus on building the clinical skills of the specialist
- Provide a robust and comprehensive clinical program that will enable a fellow to demonstrate the skills and competencies learned during the program
- Provide an environment conducive to educating fellows in each of the Accreditation Council for Graduate Medical Education (ACGME) competency areas, which are:
 - Patient Care
 - Medical Knowledge
 - Practice-Based Learning and Improvement
 - Interpersonal Communication Skills
 - Professionalism
 - System-Based Practice
- Utilize qualified faculty who devote sufficient time to the educational program to fulfill their supervisory and teaching responsibilities and demonstrate a strong interest in the education of fellow(s)
- Provide training using multi-disciplinary teams
- Adhere to all applicable regulations, guidelines, and policies

Eligibility requirements (partial list):

- Have a sponsor who is a full-time faculty member of the requesting organization
- Be U.S. Board certified or Board eligible in Neurology
 - Multiple Sclerosis Clinical Fellowship candidates must hold an active MD, DO, NP-BC or PA-C license in good standing
 - Alzheimer's Disease Clinical Fellowship candidates must hold an active MD or DO license in good standing

Citizenship: United States

Award Amount: \$90,000 for 1 year

Indirect Costs: None

Application Deadline: July 15, 2021

Website: <https://grantsandgiving.biogen.com/content/gma-grants-office/en/us/fellowships.html>

5. Spinal Cord Injury Research on the Translational Spectrum (SCIRTS) Pilot Research Grants, Craig H. Neilsen Foundation

The Neilsen Foundation funds projects that are designed to improve and advance current treatments for acute and chronic spinal cord dysfunction. This portfolio emphasizes SCI (vs. spinal cord disease or related disorders) and is intended to fill gaps in the field and to further develop new strategies to restore function resulting from SCI. The Neilsen Foundation does not

intend to provide continuous funding to individual labs but to fund novel research throughout the translational spectrum.

This funding is intended to support pilot studies that lay essential groundwork, allow the PI to test the feasibility of novel methods and procedures and/or collect new data that can lead to or enhance larger-scale studies.

Eligibility requirements (partial list):

- Non-fellowship applicants must demonstrate appropriate experience to serve as an independent Principal Investigator (PI).
- The Neilsen Foundation encourages submissions from eligible PIs who represent a wide range of disciplines; however, it is required that relevant SCI expertise is represented on the proposed research project team.

Citizenship: United States or Canada

Award Amount: \$150,000-\$300,000 paid over 1-2 years

Indirect Costs: 10%

LOI Deadline: June 11, 2021

(Invited) Application Deadline: November 16, 2021

Website: <http://chnfoundation.org/spinal-cord-injury-research-on-the-translational-spectrum/>

6. Spinal Cord Injury Research on the Translational Spectrum (SCIRTS) Postdoctoral Fellowships, Craig H. Neilsen Foundation

The Neilsen Foundation funds projects that are designed to improve and advance current treatments for acute and chronic spinal cord dysfunction. This portfolio emphasizes SCI (vs. spinal cord disease or related disorders) and is intended to fill gaps in the field and to further develop new strategies to restore function resulting from SCI. The Neilsen Foundation does not intend to provide continuous funding to individual labs but to fund novel research throughout the translational spectrum.

This funding is designed to encourage specialization in the field of SCI; Fellowships are intended to provide mentored training in SCI research to early-career investigators. The Fellowship Applicant (Fellow) should be mentored (or co-mentored) by an investigator experienced in SCI research.

Citizenship: United States or Canada

Award Amount: \$150,000 paid over 2 years

Indirect Costs: None

LOI Deadline: June 11, 2021

(Invited) Application Deadline: November 16, 2021

Website: <http://chnfoundation.org/spinal-cord-injury-research-on-the-translational-spectrum/>

7. Spinal Cord Injury Research on the Translational Spectrum (SCIRTS) Senior Research Grants, Craig H. Neilsen Foundation

The Neilsen Foundation funds projects that are designed to improve and advance current treatments for acute and chronic spinal cord dysfunction. This portfolio emphasizes SCI (vs. spinal cord disease or related disorders) and is intended to fill gaps in the field and to further develop new strategies to restore function resulting from SCI.

The grant category focuses on highly innovative projects by established PIs exploring new areas of SCI research or filling important gaps in the SCI field. The goal is not to substitute for federal funding, but to use Neilsen Foundation funds to encourage cutting-edge ideas and approaches that have great potential, despite some additional risk. The importance of the research goal should balance the risk due to the early stage of innovation.

Criteria include the innovative nature of the proposed research, the likelihood that success will move the field forward, and a history of productivity and significant contributions by the investigator.

Eligibility requirements (partial list):

- The Neilsen Foundation encourages submissions from eligible PIs who represent a wide range of disciplines; however, it is required that relevant SCI expertise is represented on the proposed research project team.

Citizenship: United States or Canada

Award Amount: \$600,000 paid over 3 years

Indirect Costs: 10%

LOI Deadline: June 11, 2021

(Invited) Application Deadline: November 16, 2021

Website: <http://chnfoundation.org/spinal-cord-injury-research-on-the-translational-spectrum/>

8. Repurposing Research Led by a US-Based Racial Minority Principal Investigator, Cures Within Reach **NEW!**

This Request for Proposals (RFP) is seeking clinical repurposing trials in any disease led by an underrepresented racial/ethnic minority clinical researcher (as defined by the NIH; <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-031.html>). CWR is interested in 1) promoting diversity, equity and inclusion in biomedical clinical research by supporting the careers of and 2) closing the NIH funding gap for underrepresented racial/ethnic groups through funding for clinical repurposing trials led by minority PIs. CWR also hopes that more representation in PIs leading clinical trials could help improve participation in clinical trials by communities of color and help address racial health disparities.

CWR is interested in both previously funded minority PIs and in supporting minority PIs who are early-stage investigators and who have received little or no extramural research funding to

date. PIs who have not received extramural funding previously and/or who do not currently have their own lab should include a Letter of Support from a funded, senior researcher who will act as a mentor for the proposed clinical trial and the PI.

Repurposed therapies can be used alone or in combination with other therapies or can be repurposed from an approved adult indication into a pediatric indication. Therapies must already be FDA, EMA or any other regulatory agency approved or otherwise readily available for human use.

We are interested in approved generic or proprietary drugs, devices, nutraceuticals or diagnostics that could be repurposed to create "new" treatments to:

- Reduce the symptoms, progression or incidence for; or
- Restore function lost to; or
- Reduce or eliminate severe side effects of currently used therapies for any unmet medical need

Only interventional clinical trials lasting no more than 36 months that treat patients to prevent disease progression and / or improve patient outcomes in unsolved diseases with a repurposed therapy are eligible for this round of funding. Clinical trials focused on preventative care to prevent new disease diagnoses are not eligible for this round of funding.

Citizenship: Unspecified

Award Amount: \$70,000

Indirect Costs: Requested project budget cannot be used for any Indirect Costs, although the 20% Institutional Match may be used for Indirect Costs.

Application Deadline: July 9, 2021

Website: <https://www.cureswithinreach.org/programs/funding-opportunities-rfps/>

9. Repurposing Research to Improve Clinical Patient Outcomes in Meniere's Disease and Related Symptoms/Consequences, Cures Within Reach **NEW!**

This Request for Proposals is seeking preclinical repurposing research projects to address Meniere's disease (MD) and symptoms/consequences of MD, including tinnitus and hearing loss. We are interested in generic or proprietary drugs, devices, nutraceuticals or diagnostics that could ultimately be repurposed to create "new" treatments to 1) reduce the symptoms, progression or incidence of; 2) restore function lost to; or 3) to reduce or eliminate severe side effects of currently used therapies for MD and/or related symptoms/consequences, including tinnitus and hearing loss, thereby improving patient outcomes and quality of life.

Repurposed therapies can be used alone or in combination with other therapies. Repurposed therapies must be approved and/or recognized as safe for human use by some regulatory agency, such as the US Food and Drug Administration, European Medicines Agency, Health Canada or Japan's Pharmaceuticals and Medical Devices Agency.

Our strongest preference is for late stage preclinical repurposing research projects that are the last step(s) before moving into patients. We will also consider other types of earlier stage preclinical repurposing research, including drug screening, bioinformatics, genotyping or 'omics studies, cell-based assays and animal models. We will accept projects that already have funding from another source and require additional funding, when this additional funding from Cures Within Reach will help improve the chances of success of the project.

Citizenship: Unspecified

Award Amount: \$25,000-\$50,000

Indirect Costs: Requested project budget cannot be used for any Indirect Costs, although the 20% Institutional Match may be used for Indirect Costs.

Application Deadline: May 26, 2021

Website: <https://www.cureswithinreach.org/programs/funding-opportunities-rfps/>

10. Repurposing Research to Improve Clinical Patient Outcomes in Meniere's Disease and Related Symptoms/Consequences, Cures Within Reach **NEW!**

This Request for Proposals is seeking clinical repurposing trials to address Meniere's disease (MD) and symptoms/consequences of MD, including tinnitus and hearing loss. We are interested in generic or proprietary drugs, devices, nutraceuticals or diagnostics that could be repurposed to create "new" treatments to 1) reduce the symptoms, progression or incidence of; 2) restore function lost to; or 3) to reduce or eliminate severe side effects of currently used therapies for MD and/or related symptoms/consequences, including tinnitus and hearing loss, thereby improving patient outcomes and quality of life.

Repurposed therapies can be used alone or in combination with other therapies. Repurposed therapies must be approved and/or recognized as safe for human use by some regulatory agency, such as the US Food and Drug Administration, European Medicines Agency, Health Canada or Japan's Pharmaceuticals and Medical Devices Agency.

Our strongest preference is for proof of concept repurposing clinical research trials supported by strong preclinical evidence or clinical observations. We may also consider later stage clinical trials that require additional funding if our additional funding will help speed the patient impact of the clinical trial.

Citizenship: Unspecified

Award Amount: \$25,000-\$100,000

Indirect Costs: Requested project budget cannot be used for any Indirect Costs, although the 20% Institutional Match may be used for Indirect Costs.

Application Deadline: May 26, 2021

Website: <https://www.cureswithinreach.org/programs/funding-opportunities-rfps/>

11. FamilieSCN2A Action Potential Grant, FamilieSCN2A Foundation

Through our investigator-initiated grant program, the FamilieSCN2A Foundation hopes to accelerate the development of therapeutic treatments and disease-modifying advancements for those living with changes in the SCN2A gene. This grant program is designed to facilitate preliminary investigations that will potentially lay the groundwork for subsequent grants from the government, industry, or other funding sources, including the FamilieSCN2A Foundation.

The FamilieSCN2A Foundation is interested in supporting research that advances understanding of the cellular, molecular, genetic and systems-level mechanisms of SCN2A related disorders. However, priority will be given to innovative projects which could potentially lead to therapeutic treatments or a cure for those with SCN2A related disorders.

Citizenship: Unrestricted

Award Amount: \$50,000 for 1 year

Indirect Costs: None

LOI Deadline: June 1, 2021

Application Deadline: July 1, 2021

Website: <https://www.scn2a.org/professionals.html>

12. IOIBD Operating Grants, International Organization For the Study of Inflammatory Bowel Disease (IOIBD)

The mission of the IOIBD is to promote the health of people with IBD worldwide by setting the direction for patient care, education and research.

A short presentation of the project outcome will be made during the next annual meeting by the sponsor.

Applicants must have an active or senior IOIBD member as PI or co-investigator.

Citizenship: Unrestricted

Award Amount: Up to €200,000 (approx. \$240,000) for 1 year

Indirect Costs: 10%

Application Deadline: June 30, 2021

Website: <http://www.ioibd.org/grants/>

13. Bipolar Disorder Grant Program, Milken Institute **NEW!**

The Baszucki Brain Research Fund is launching a new program focused on funding bipolar disorder research in collaboration with Milken Institute Center for Strategic Philanthropy. The Milken Institute is now accepting applications for one-year research projects that seek to advance therapeutic discovery for bipolar disorder to improve treatment options for

individuals living with bipolar.

The scientific focus of bipolar disorder proposals shall address one or more of the following broad focus areas in humans or relevant research models:

- Proof of concept studies for novel treatment approaches
- Comparative assessment of novel or underutilized approaches to standard clinical practice
- The novel application of therapies not currently used to treat bipolar disorder
- Advancement of the application of neural devices to bipolar disorder
- Application of new tools or technologies to identify subpopulations of patients that may differentially respond to a treatment approach
- Research that deepens our understanding of how existing or novel therapies affect bipolar disorder

Citizenship: Unrestricted

Award Amount: \$200,000

Indirect Costs: 15%

LOI Deadline: May 14, 2021

(Invited) Application Deadline: July 9, 2021

Website: <https://milkeninstitute.org/reports/bipolar-disorder-proposals>

14. Clinical Care Physician Fellowship, National Multiple Sclerosis Society (NMSS)

The National Multiple Sclerosis Society offers a one year, post-residency MS clinical fellowship program designed to train board eligible/certified neurologists or physiatrists in specialized MS clinical care. The program is sponsored by the National Multiple Sclerosis Society.

This program for board eligible/certified neurologists or physiatrists provides fellows with the opportunity to perform new patient consultations and follow-up evaluations under the supervision of an MS specialist physician. Fellows will also participate in multidisciplinary team activities, lectures, and professional meetings, leading to the acquisition of skills and knowledge necessary to provide the highest quality of care for individuals with MS.

Eligibility requirements (partial list):

- Residents who have or will have received training in neurology or physiatry in the United States, and who are in the PGY3 or PGY4 stage or beyond, are eligible to apply.
- Residents whose career plans include working with underserved populations or in rural areas are particularly encouraged to apply.

Citizenship: United States

Award Amount: \$75,000 for 1 year

Indirect Costs: 10%

Pre-Application Deadline: July 28, 2021

Full Application Deadline: August 4, 2021

Website: <http://www.nationalmssociety.org/For-Professionals/Clinical-Care/Resources-for-You-and-Your-Practice/Clinical-Fellowships-and-Grants/MS-Clinical-Care-Physician-Fellowship>

15. Rising Star Research Awards, One Mind Institute (formerly IMHRO)

The goal of the Rising Star Research Awards is to recognize and fund promising, early career investigators through a competitive grants process to accelerate research on major neuropsychiatric disorders.

Proposals for a Rising Star Research Award that are directed at understanding fundamental characteristics and biological mechanisms of brain function and dysfunction are within scope, as well as the translation of basic science mechanisms into better diagnostics and treatments for neuropsychiatric disorders. Note that proposals on schizophrenia research are of particular interest.

Eligibility requirements (partial list):

- To qualify as an early career investigator, candidates should be within 10 years of their initial independent appointment.

Citizenship: United States

Award Amount: \$300,000 paid over 3 years

Indirect Costs: 10%

Application Deadline: June 1, 2021

Website: <https://onemind.org/guiding-focus/rising-star-awards/>

16. Burden of Community Acquired Pneumonia, Pfizer Global Medical Grants (GMG) **NEW!**

Studies that will be considered for Pfizer support will focus on evaluating the burden of community acquired pneumonia, including but not limited to pneumococcal pneumonia, as well as risk factors for and complications from disease.

Projects submitted may include:

- Quantification of the disease burden of community acquired pneumonia in adult population
- Exacerbations of chronic disease (e.g., CHF, diabetes, others) either leading to hospitalization or following hospitalization due to community acquired pneumonia
- Long term declines in quality of life following pneumococcal disease syndromes (pneumonia, IPD)
- Quantification of impact of risk factor for community acquired pneumonia/ pneumococcal disease
- Identification of new risk factors for community acquired pneumonia / pneumococcal disease

Citizenship: United States

Award Amount: \$150,000

Indirect Costs: 28%

Application Deadline: June 9, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

17. Closing Knowledge Gaps in Moderate-to-Severe Alopecia Areata, Pfizer Global Medical Grants (GMG) **NEW!**

Projects that will be considered for Pfizer support should focus on increasing the knowledge and understanding of: 1) the pathophysiology of alopecia areata with specific focus on immunologic pathways, including how the pathway differs from other causes of hair loss; and 2) the epidemiology of alopecia areata, including an understanding of the risk factors; and 3) understanding the clinical manifestation of alopecia areata, including a holistic review of the burden of disease (e.g. psychosocial burden and associated autoimmune disorders).

NOTE: It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Citizenship: United States

Award Amount: \$300,000

Indirect Costs: 28%

Application Deadline: May 26, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

18. Development of Talazoparib for Prostate Cancer, Pfizer Global Medical Grants (GMG) **NEW!**

The overall aim is to develop innovative investigations to help determine the role of talazoparib and foster the development of PARPi in prostate cancer. Proposals should focus on clinical development of talazoparib alone or in combinations, understanding the biologic mechanisms of talazoparib, or defining optimal patient factors and other predictive biomarkers of clinical benefit. Both clinical trials with correlative endpoints and basic research proposals are encouraged.

Citizenship: United States

Award Amount: A total of \$1.5 million is available to fund selected projects. It is anticipated that 3-5 projects will be awarded funding.

Indirect Costs: 28%

LOI Deadline: June 21, 2021

(Invited) Application Deadline: September 24, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

19. NSCLC Biomarker Testing, Pfizer Global Medical Grants (GMG) **NEW!**

Projects that will be considered for Pfizer support will be Quality Improvement initiatives that analyze and improve biomarker testing practices in NSCLC.

For patients diagnosed with metastatic NSCLC, sub-optimal biomarker testing practices continue to exist. A high percentage of patients are initiated on therapy before the care team receives the results of a comprehensive biomarker testing panel. For some patients, standardized biomarker tests are not performed at all.

Grant support is available to cancer centers or hospitals interested in forming multi-disciplinary teams to analyze their own testing practices and identify areas of improvement using Quality Improvement (QI) methodology such as root cause analysis, Plan Do Study Act (PDSA) cycles etc.

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Citizenship: See announcement for full list

Award Amount: \$150,000

Indirect Costs: 28%

Application Deadline: June 23, 2021

Website: <https://www.pfizer.com/purpose/independent-grants/competitive-grants>

20. Health Equity Scholars for Action, Robert Wood Johnson Foundation (RWJF) **NEW!**

A guiding principle of RWJF is that “we seek bold and lasting change rooted in the best available evidence, analysis, and science, openly debated.” Health Equity Scholars for Action (HES4A) is designed to enhance the supports, resources, and community necessary for participants to thrive professionally and personally, and in turn, be better able to contribute to and expand health equity-related research and evidence that can help build a Culture of Health.

The goal of HES4A is to support the career development and academic advancement of researchers from historically underrepresented backgrounds who conduct health equity research. Grants will be awarded to address the challenges that underrepresented researchers experience; help them overcome obstacles to earning tenure; and make progress toward acquiring independent research funding. Grants will support three aspects of career development: research, mentorship, and connection with a community of support.

Eligibility requirements (partial list):

- To be eligible for HES4A, the individual applicant must be from a systematically marginalized group that has historically been underrepresented in research disciplines.

The term “systematically marginalized” refers to the challenges facing individuals because of their race, ethnicity, gender expression or sexual orientation, socioeconomic status, or similar factors. Eligible individuals include, but are not limited to:

- Individuals from ethnically and racially minoritized groups underrepresented in research disciplines
 - First-generation college graduates
 - People for whom English is not a native language
 - People from low-income communities
 - LGBTQ+ individuals
 - Individuals with disabilities
- Have completed a doctoral degree within the last five years. The degree can be in any field and is not limited to public health or health sciences.
 - Be a junior faculty member in an accredited school in the U.S. or its territories, with a full-time academic position that could lead to tenure, or a postdoctoral fellow poised to be in such a position by the start of the grant.
 - Have never served as a project director or principal investigator on any grant since receiving their doctoral degree. Individuals who have been awarded grants to support predoctoral training or have received a predoctoral fellowship grant are eligible to apply.

Citizenship: U.S. citizen, permanent resident, or granted Deferred Action for Childhood Arrivals (DACA) status by the U.S. Citizenship and Immigration Services at the time of application.

Award Amount: \$250,000 paid over 2 years

Indirect Costs: 12%

LOI Deadline: June 16, 2021

(Invited) Application Deadline: September 1, 2021

Website: <https://www.rwjf.org/en/library/funding-opportunities/2021/health-equity-scholars-for-action.html>